ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MPLT vs PHAT // DIVIDEND YIELD & FCF PAYOUT SAFETY

MapLight Therapeutics Inc. (NASDAQ) VS. Phathom Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: MPLT 1 — PHAT 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MPLT VS. PHAT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MPLT PHAT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 87.10% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -32.40% -35.00% +2.60 MPLT /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -0.10% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 PHAT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 33.9 41.5 -7.60 PHAT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $500.1M $503.2M -$3.2M PHAT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MPLT REV PHAT REV MPLT GROSS % PHAT GROSS % MPLT FCF PHAT FCF
FY 2025 $0 $175.1M — 87.1% -$138.6M -$167.0M
FY 2024 $0 $55.3M — 85.6% -$79.6M -$266.9M
FY 2023 — $682.0K — — — -$137.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MPLT // BETA —
PHAT // BETA —